Gurtsieva, D.; Minskaia, E.; Zhuravleva, S.; Subcheva, E.; Sakhibgaraeva, E.; Brovin, A.; Tumaev, A.; Karabelsky, A.
Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes. Pharmaceutics 2024, 16, 138.
https://doi.org/10.3390/pharmaceutics16010138
AMA Style
Gurtsieva D, Minskaia E, Zhuravleva S, Subcheva E, Sakhibgaraeva E, Brovin A, Tumaev A, Karabelsky A.
Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes. Pharmaceutics. 2024; 16(1):138.
https://doi.org/10.3390/pharmaceutics16010138
Chicago/Turabian Style
Gurtsieva, Dzerassa, Ekaterina Minskaia, Sofia Zhuravleva, Elena Subcheva, Elena Sakhibgaraeva, Andrew Brovin, Artem Tumaev, and Alexander Karabelsky.
2024. "Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes" Pharmaceutics 16, no. 1: 138.
https://doi.org/10.3390/pharmaceutics16010138
APA Style
Gurtsieva, D., Minskaia, E., Zhuravleva, S., Subcheva, E., Sakhibgaraeva, E., Brovin, A., Tumaev, A., & Karabelsky, A.
(2024). Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes. Pharmaceutics, 16(1), 138.
https://doi.org/10.3390/pharmaceutics16010138
